Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
09/09/20 Alkermes to Take Part in Cantor Virtual Global Healthcare Conference
09/08/20 Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
08/21/20 Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
08/19/20 Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors
08/17/20 American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
07/29/20 Alkermes Releases Third Annual Corporate Responsibility Report
07/29/20 Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
07/27/20 New Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic
07/22/20 Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results
06/29/20 Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
06/24/20 Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
06/22/20 New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
06/04/20 Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
06/02/20 Alkermes Response to Current Events
05/27/20 Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
Displaying 16 - 30 of 795